Supporting Information
Control
Low dose (15 mg/kg/day)
High dose (60 mg/kg/day)
Fe
Mo
Composite
Zn
Figure S1. The distribution of Fe, Mo and Zn and composite images (red: Fe, green: Zn,
blue: Mo) in rat kidney sections. Left: Kidney section (4 µm) from a control animal; Middle:
Kidney section (20 µm) from a rat given 15 mg/kg/day TTM; Right: Kidney section (4 µm)
from a rat given 60 mg/kg/day TTM. The colour scale indicates the concentration of Mo in
tissue in mg kg−1 and the intensities of 56Fe and 64Zn signals in counts per pixel.
Control
Low dose (15 mg/kg/day)
High dose (60 mg/kg/day)
Cu
Mo
Composite
Zn
Figure S2. The distribution of Cu, Mo and Zn and composite images (red: Cu, green: Zn,
blue: Mo) in rat kidney sections. Left: Kidney section (4 µm) from a control animal; Middle:
Kidney section (20 µm) from a rat given 15 mg/kg/day TTM; Right: Kidney section (4 µm)
from a rat given 60 mg/kg/day TTM. The colour scale indicates the concentrations of Cu and
Mo in tissue in mg kg−1 and the intensity of 64Zn signals in counts per pixel.
30%
Fraction of pixels
25%
Control group (G3)
Low-dosage group (G2)
High-dosage group (G1)
20%
15%
10%
5%
0%
1.3
5
9
12
16
20
23
27
31
-1
Concentration of Mo, mg kg
Figure S3. Average histograms of Mo distribution in liver sections taken from three rats in
each of the TTM dosage groups. Error bars correspond to 1sd (n=3).
20
18
16
Control group (G3)
Low-dosage group (G2)
High-dosage group (G1)
Fraction of pixels, %
14
12
10
8
6
4
2
0
1
7
13
19
25 31 37 43 49 55 61
Concentration of Mo, mg kg-1
67
73
79
Figure S4. Average histograms of Mo distribution in spleen sections taken from three rats in
each of the TTM dosage groups. Error bars correspond to 1sd (n=3).
Cu
Mo
Zn
Composite
Figure S5. The distribution of Cu, Mo and Zn and a composite image (red: Cu, green: Zn,
blue: Mo) in a 20 µm brain section of a rat administered with 15 mg TTM/kg/day (see Fig.
12). The colour scale indicates the concentrations of Cu and Mo in tissue in mg kg−1 and the
intensity of 64Zn signals in counts per pixel.
45%
40%
Fraction of pixels
35%
Control group (G3)
Low-dosage group (G2)
High-dosage group (G1)
30%
25%
20%
15%
10%
5%
0%
1
4
6
8
11 13 16 18 20 23
Concentration of Mo, mg kg-1
25
28
30
Figure S6. Average histograms of Mo distribution in brain sections taken from three rats
from each of the TTM dosage groups. Error bars correspond to 1sd (n=3).
Table S1. Summary of clinical biochemistry parameters in male rats following treatment
with bis-choline tetrathiomolybdate.
Male
Test
Parameters
A/G
GGT
(U/L)
PA
(mg/L)
TBIL
(umol/L)
DBIL
(umol/L)
TP
(g/L)
ALB
(g/L)
GLB
(g/L)
ALT
(U/L)
AST
(U/L)
ALP
(U/L)
LDH
(U/L)
BUN
(mmol/L)
CR
(µmol/L)
Groups
G1
G2
G3
G1
G2
G3
G1
G2
G3
G1
G2
G3
G1
G2
G3
G1
G2
G3
G1
G2
G3
G1
G2
G3
G1
G2
G3
G1
G2
G3
G1
G2
G3
G1
G2
G3
G1
G2
G3
G1
G2
G3
Pre-dose
1.53 ± 0.05
1.57 ± 0.04
1.53 ± 0.03
0.90 ± 0.18
0.83 ± 0.22
0.63 ± 0.11
21.1 ± 0.9
20.2 ± 0.6
18.4 ± 1.4
<LOD
<LOD
<LOD
<LOD
<LOD
<LOD
60.7 ± 1.3
58.2 ± 1.3
59.0 ± 0.6
36.6 ± 0.7
35.5 ± 0.7
35.7 ± 0.4
24.1 ± 0.7
22.7 ± 0.7
23.3 ± 0.4
58.2 ± 3.2
51.9 ± 3.7
53.4 ± 3.5
162 ± 12
143 ± 13
125 ± 10
380 ± 14
398 ± 33
404 ± 25
1950 ± 337*
1273 ± 240
897 ± 171
5.09 ± 0.16**
5.61 ± 0.23
6.50 ± 0.31
16.0 ± 1.3
16.0 ± 1.3
16.0 ± 2.0
Treatment
4 weeks
1.22 ± 0.03
1.28 ± 0.03
1.23 ± 0.03
1.15 ± 0.33
1.38 ± 0.28
0.85 ± 0.23
43.1 ± 1.5
35.4 ± 1.8
41.3 ± 4.9
2.42 ± 0.19**
1.98 ± 0.10**
0.25 ± 0.08
0.88 ± 0.06**
0.92 ± 0.05**
0.48 ± 0.03
69.0 ± 0.9*
66.8 ± 1.5
66.3 ± 0.5
37.9 ± 0.3**
37.7 ± 0.6
36.4 ± 0.3
31.1 ± 0.8
29.1 ± 1.0
29.9 ± 0.5
57.4 ± 4.1
51.1 ± 3.1
45.8 ± 2.6
106 ± 4
109 ± 3
103 ± 11
242 ± 8
266 ± 27
238 ± 12
631 ± 116
648 ± 113
516 ± 168
4.87 ± 0.23
5.16 ± 0.50
5.26 ± 0.41
38.8 ± 1.6
45.3 ± 1.4
42.7 ± 2.8
8 weeks
1.18 ± 0.04
1.22 ± 0.03
1.17 ± 0.02
1.03 ± 0.13
1.05 ± 0.29
0.52 ± 0.15
3.3 ± 0.9
0.9 ± 0.2
2.5 ± 1.0
3.43 ± 0.22**
2.77 ± 0.29**
0.43 ± 0.14
1.03 ± 0.09*
1.10 ± 0.07**
0.68 ± 0.05
71.1 ± 1.3
70.1 ± 1.6
68.3 ± 0.5
38.5 ± 0.6
38.8 ± 0.5*
36.7 ± 0.4
32.6 ± 1.1
31.4 ± 1.1
31.6 ± 0.5
56.0 ± 3.2
52.4 ± 4.1
49.1 ± 2.9
97 ± 8
111 ± 8
101 ± 8
172 ± 10
189 ± 20
162 ± 9
362 ± 88
653 ± 114
467 ± 170
6.03 ± 0.18*
5.45 ± 0.41
5.16 ± 0.15
24.2 ± 0.9**
30.8 ± 1.2
31.5 ± 1.0
12 weeks
1.20 ± 0.03
1.22 ± 0.03
1.15 ± 0.02
0.53 ± 0.07
0.38 ± 0.12
0.60 ± 0.12
4.0 ± 0.6
3.3 ± 0.5
3.0 ± 0.7
3.37 ± 0.18**
2.57 ± 0.24**
0.30 ± 0.05
1.35 ± 0.14**
1.17 ± 0.07**
0.53 ± 0.03
71.1 ± 1.2
69.8 ± 1.2
69.8 ± 0.7
38.7 ± 0.5
38.2 ± 0.5
37.1 ± 0.6
32.4 ± 1.0
31.6 ± 0.8
32.7 ± 0.5
53.4 ± 4.5
45.9 ± 2.8
41.2 ± 2.9
159 ± 15
150 ± 10
145 ± 16
133 ± 7
145 ± 19
118 ± 7
2141 ± 392
2171 ± 215
1688 ± 223
6.20 ± 0.25*
5.38 ± 0.21
5.25 ± 0.21
24.2 ± 1.0
26.0 ± 0.8
26.7 ± 0.8
UA
(µmol/L)
ADA
(U/L)
G1
G2
G3
G1
G2
G3
96.2 ± 5.8
80.9 ± 6.3
88.3 ± 5.7
23.0 ± 9.7
25.0 ± 14.0
12.8 ± 5.0
92.0 ± 11.8
83.9 ± 8.3
70.5 ± 9.2
29.6 ± 15.3
59.1 ± 33.2
23.8 ± 9.3
65.3 ± 7.0
75.6 ± 8.2
81.5 ± 9.1
22.3 ± 7.6
43.3 ± 26.8
19.9 ± 9.4
96.9 ± 11.9
79.1 ± 6.9
81.1 ± 6.9
17.8 ± 5.4
34.2 ± 21.9
18.4 ± 6.2
Notes: G1 = 60 mg/kg/day; G2 = 15 mg/kg/day; G3 = vehicle control. A/G = albumin to globulin
ratio; GGT = gamma-glutamyltransferase; PA = pre albumin; TBil = total bilirubin; DBil =
unconjugated bilirubin; TP = total protein; ALB = albumin; GLB = globulin; ALT = alanine
aminotransaminase; AST = aspartate aminotransaminase; ALP = alkaline phosphatase; LDH = lactate
dehydrogenase: BUN = blood urea nitrogen; CRE = creatinine; UA = uric acid; ADA = adenosine
deaminase. Values are expressed as mean ± SE of 6 rats in each group. * and ** indicate a significant
difference at p < 0.05 and p < 0.01 level, respectively, when compared to G3 (vehicle control
group). <LOD means that the values are beneath the limit of detection.
Table S2: Summary of clinical biochemistry parameters in female rats following treatment
with bis-choline tetrathiomolybdate.
Female
Test
Parameters
A/G
GGT
(U/L)
PA
(mg/L)
TBIL
(µmol/L)
DBIL
(µmol/L)
TP
(g/L)
ALB
(g/L)
GLB
(g/L)
ALT
(U/L)
Groups
G1
G2
G3
G1
G2
G3
G1
G2
G3
G1
G2
G3
G1
G2
G3
G1
G2
G3
G1
G2
G3
G1
G2
G3
G1
G2
G3
G1
Pre-dose
1.72 ± 0.04
1.65 ± 0.05
1.68 ± 0.05
0.63 ± 0.14
0.83 ± 0.15*
0.23 ± 0.05
<LOD
<LOD
<LOD
<LOD
<LOD
<LOD
<LOD
<LOD
<LOD
64.9 ± 1.4
61.6 ± 0.8
62.7 ± 1.1
41.1 ± 0.7
38.2 ± 0.6
39.4 ± 0.9
23.8 ± 0.7
23.4 ± 0.5
23.3 ± 0.4
50.8 ± 2.3
51.3 ± 6.6
56.7 ± 2.3
159 ± 7*
Treatment
4 weeks
1.37 ± 0.03
1.37 ± 0.03
1.37 ± 0.04
1.75 ± 0.32
1.73 ± 0.20
1.35 ± 0.45
35.9 ± 3.3
37.1 ± 2.6
37.3 ± 3.6
3.43 ± 0.31**
2.70 ± 0.16**
0.48 ± 0.14
1.05 ± 0.10**
0.80 ± 0.04*
0.58 ± 0.06
74.4 ± 1.4
72.7 ± 1.4
71.6 ± 0.6
43.0 ± 1.1
41.9 ± 1.0
41.3 ± 0.6
31.4 ± 0.4
30.8 ± 0.6
30.3 ± 0.6
67.8 ± 11.4
48.1 ± 1.1
59.4 ± 13.2
110 ± 5
8 weeks
1.37 ± 0.02
1.33 ± 0.02
1.38 ± 0.03
0.68 ± 0.14
0.82 ± 0.10
0.55 ± 0.24
<LOD
<LOD
2.2 ± 0.6
3.87 ± 0.32**
2.95 ± 0.15**
0.95 ± 0.14
1.05 ± 0.11*
0.73 ± 0.06
0.63 ± 0.07
78.8 ± 1.7
76.5 ± 1.4
75.6 ± 1.8
45.7 ± 1.2
43.8 ± 1.0
43.6 ± 1.2
33.1 ± 0.6
32.6 ± 0.6
32.0 ± 0.7
68.7 ± 15.7
45.1 ± 1.5
63.5 ± 10.1
134 ± 23
12 weeks
1.42 ± 0.02
1.38 ± 0.03
1.38 ± 0.03
0.62 ± 0.22
0.45 ± 0.10
0.28 ± 0.10
3.3 ± 0.8
4.3 ± 0.2
5.4 ± 0.7
4.13 ± 0.18**
3.73 ± 0.43**
1.28 ± 0.21
1.08 ± 0.08*
1.03 ± 0.09*
0.68 ± 0.09
77.6 ± 1.1
75.4 ± 1.6
77.4 ± 2.4
45.5 ± 0.6
43.7 ± 1.1
45.1 ± 1.5
32.1 ± 0.6
31.7 ± 0.6
32.3 ± 1.0
56.5 ± 8.8
43.0 ± 5.7
45.2 ± 5.8
144 ± 16
AST
(U/L)
ALP
(U/L)
LDH
(U/L)
BUN
(mmol/L)
CR
(µmol/L)
UA
(µmol/L)
ADA
(U/L)
G2
G3
G1
G2
G3
G1
G2
G3
G1
G2
G3
G1
G2
G3
G1
G2
G3
G1
G2
G3
144 ± 18
121 ± 12
172 ± 12
190 ± 21
196 ± 17
1799 ± 111*
1162 ± 155
859 ± 220
6.13 ± 0.25
6.11 ± 0.43
6.35 ± 0.19
22.0 ± 2.0
19.0 ± 1.0
22.0 ± 1.3
93.1 ± 2.2*
91.0 ± 10.0
77.9 ± 4.0
52.1 ± 22.4
32.0 ± 11.2
27.1 ± 8.3
113 ± 7
149 ± 25
95 ± 7
107 ± 12
96 ± 9
619 ± 77
555 ± 82
875 ± 114
6.03 ± 0.33
6.97 ± 0.49
6.25 ± 0.21
34.5 ± 2.6**
44.3 ± 3.0
46.8 ± 1.5
80.5 ± 7.5
84.9 ± 6.4
76.0 ± 4.9
34.8 ± 16.2
17.8 ± 5.7
19.6 ± 7.6
140 ± 33
164 ± 36
60 ± 6
68 ± 10
64 ± 4
813 ± 192
561 ± 112
517 ± 135
7.28 ± 0.22
7.62 ± 0.58
6.33 ± 0.52
28.2 ± 1.9
33.7 ± 2.1
36.8 ± 2.7
76.4 ± 6.0
64.6 ± 2.4
60.6 ± 4.7
12.6 ± 5.7
11.2 ± 4.9
4.9 ± 1.1
140 ± 41
141 ± 25
48 ± 5
50 ± 6
46 ± 3
1212 ± 158
857 ± 214
1262 ± 250
6.68 ± 0.23
6.95 ± 0.60
5.93 ± 0.33
26.0 ± 1.8*
42.8 ± 9.5
32.0 ± 1.2
64.1 ± 6.8
167.4 ± 89.6
82.6 ± 19.9
13.8 ± 5.7
11.9 ± 4.4
4.7 ± 0.9
Notes: G1 = 60 mg/kg/day; G2 = 15 mg/kg/day; G3 = vehicle control. A/G = albumin to globulin
ratio; GGT = gamma-glutamyltransferase; PA = pre albumin; TBil = total bilirubin; DBil =
unconjugated bilirubin; TP = total protein; ALB = albumin; GLB = globulin; ALT = alanine
aminotransaminase; AST = aspartate aminotransaminase; ALP = alkaline phosphatase; LDH = lactate
dehydrogenase; BUN = blood urea nitrogen; CRE = creatinine; UA = uric acid; ADA = adenosine
deaminase. Values are expressed as mean ± SE of 6 rats in each group. * and ** indicates a significant
difference at p < 0.05 and p < 0.01 level, respectively, when compared to G3 (vehicle control
group). <LOD means that the values are beneath the limit of detection
Table S3. Hematological parameters of male animals treated with bis-choline
tetrathiomolybdate.
Test
Parameters
WBC (109/L)
NEU (%)
LYM
(%)
MON
(%)
EOS
(%)
Male
Groups
G1
G2
G3
G1
G2
G3
G1
G2
G3
G1
G2
G3
G1
G2
G3
G1
Pre-dose
13.8 ± 1.0
12.0 ± 1.2
11.4 ± 0.6
10.4 ± 1.4
11.9 ± 1.4
12.1 ± 1.6
87.1 ± 1.7
85.5 ± 1.6
85.0 ± 1.6
1.92 ± 0.26
1.98 ± 0.27
2.10 ± 0.23
0.48 ± 0.10
0.62 ± 0.09
0.70 ± 0.15
0.08 ± 0.02
Treatment
4 weeks
14.8 ± 1.3
13.3 ± 2.0
10.3 ± 0.4
12.0 ± 2.1
10.9 ± 1.5
13.9 ± 1.6
85.3 ± 2.1
84.6 ± 2.1
82.7 ± 1.9
1.97 ± 0.16
2.58 ± 0.31
2.15 ± 0.16
0.65 ± 0.13
1.82 ± 0.95
1.23 ± 0.29
0.12 ± 0.02
8 weeks
12.3 ± 1.2
11.6 ± 2.0
9.8 ± 0.9
10.5 ± 1.2
12.4 ± 1.6
14.4 ± 2.4
86.1 ± 1.1
83.6 ± 1.6
81.7 ± 2.6
2.43 ± 0.36
3.00 ± 0.36
2.27 ± 0.44
0.98 ± 0.14
1.00 ± 0.13
1.53 ± 0.31
0.05 ± 0.02
12 weeks
11.1 ± 1.1
10.2 ± 1.0
8.7 ± 0.9
12.8 ± 2.0
14.9 ± 1.7
16.3 ± 1.5
83.2 ± 2.5
80.8 ± 1.8
79.8 ± 1.5
3.03 ± 0.46
3.20 ± 0.38
2.55 ± 0.26
0.97 ± 0.15
1.07 ± 0.14
1.35 ± 0.23
0.03 ± 0.02
G2
G3
G1
NEU (109/L)
G2
G3
G1
LYM (109/L) G2
G3
G1
9
MON (10 /L) G2
G3
G1
9
G2
EOS (10 /L)
G3
G1
9
BAS (10 /L)
G2
G3
G1
12
RBC (10 /L) G2
G3
G1
HGB (g/L)
G2
G3
G1
HCT
G2
(%)
G3
G1
MCV
G2
(fL)
G3
G1
MCH
G2
(pg)
G3
G1
MCHC (g/L)
G2
G3
G1
RDW-SD (fL) G2
G3
G1
RDW-CV (%) G2
G3
G1
PLT (109/L)
G2
G3
G1
MPV
G2
(fL)
G3
G1
PCT
G2
(%)
G3
BAS
(%)
0.07 ± 0.02
0.07 ± 0.02
1.40 ± 0.16
1.35 ± 0.09
1.42 ± 0.22
12.02 ± 0.98
10.30 ± 1.24
9.68 ± 0.43
0.27 ± 0.04
0.22 ± 0.03
0.23 ± 0.03
0.06 ± 0.01
0.07 ± 0.01
0.08 ± 0.02
0.01 ± 0.00
0.01 ± 0.00
0.01 ± 0.00
7.07 ± 0.17
6.92 ± 0.27
6.91 ± 0.13
144 ± 5
141 ± 4
144 ± 3
43.6 ± 1.1
42.8 ± 1.2
43.7 ± 0.7
61.7 ± 0.6
62.0 ± 0.9
63.3 ± 0.7
20.3 ± 0.3
20.4 ± 0.3
20.9 ± 0.2
329 ± 3
329 ± 2
330 ± 2
30.0 ± 1.0
29.2 ± 0.5
30.6 ± 0.7
14.0 ± 0.5
13.7 ± 0.2
13.9 ± 0.3
989 ± 57
984 ± 53
870 ± 79
8.17 ± 0.09
8.13 ± 0.11
8.30 ± 0.12
0.81 ± 0.04
0.80 ± 0.05
0.72 ± 0.07
0.12 ± 0.02
0.05 ± 0.02
1.67 ± 0.22
1.38 ± 0.21
1.43 ± 0.20
12.68 ± 1.34*
11.42 ± 1.90
8.47 ± 0.16
0.28 ± 0.04
0.30 ± 0.04
0.23 ± 0.02
0.09 ± 0.01
0.19 ± 0.07
0.13 ± 0.03
0.02 ± 0.00**
0.02 ± 0.00*
0.01 ± 0.00
8.72 ± 0.18*
8.62 ± 0.16*
8.11 ± 0.06
170 ± 3
168 ± 3
161 ± 1
49.9 ± 0.9*
49.2 ± 0.7*
46.8 ± 0.4
57.2 ± 0.5
57.1 ± 0.7
57.7 ± 0.7
19.5 ± 0.3
19.5 ± 0.2
19.9 ± 0.2
341 ± 3
342 ± 1
345 ± 2
24.6 ± 0.5
24.6 ± 0.3*
25.9 ± 0.3
14.5 ± 0.4
14.4 ± 0.4
14.0 ± 0.3
908 ± 40
693 ± 105
954 ± 48
8.65 ± 0.12
8.47 ± 0.06
8.33 ± 0.07
0.78 ± 0.04
0.59 ± 0.09
0.80 ± 0.04
0.03 ± 0.02
0.10 ± 0.06
1.28 ± 0.21
1.32 ± 0.15
1.40 ± 0.26
10.55 ± 1.03
9.77 ± 1.77
7.98 ± 0.77
0.32 ± 0.07
0.38 ± 0.13
0.25 ± 0.06
0.11 ± 0.01
0.11 ± 0.02
0.16 ± 0.04
0.01 ± 0.00
0.00 ± 0.00
0.01 ± 0.01
8.88 ± 0.18
8.98 ± 0.15*
8.19 ± 0.22
162 ± 2
166 ± 2*
154 ± 3
48.0 ± 0.6*
48.5 ± 0.7**
45.0 ± 0.6
54.1 ± 0.7
54.1 ± 0.8
55.1 ± 0.9
18.3 ± 0.2
18.5 ± 0.2
18.9 ± 0.2
338 ± 2
342 ± 1
343 ± 3
24.8 ± 0.7
25.6 ± 0.7
26.2 ± 0.5
16.2 ± 0.2
16.6 ± 0.1
15.7 ± 0.5
789 ± 46
837 ± 47
858 ± 65
8.00 ± 0.11
7.95 ± 0.06
8.02 ± 0.13
0.63 ± 0.04
0.67 ± 0.04
0.69 ± 0.06
0.02 ± 0.02
0.02 ± 0.02
1.37 ± 0.21
1.53 ± 0.21
1.42 ± 0.17
9.28 ± 1.09
8.28 ± 0.83
6.92 ± 0.74
0.33 ± 0.06
0.30 ± 0.03
0.22 ± 0.03
0.10 ± 0.01
0.11 ± 0.02
0.12 ± 0.03
0.00 ± 0.00
0.00 ± 0.00
0.00 ± 0.00
8.96 ± 0.15
9.29 ± 0.24
8.71 ± 0.10
165 ± 3
169 ± 3
162 ± 2
48.1 ± 0.7
49.5 ± 1.0
47.4 ± 0.4
53.7 ± 0.5
53.4 ± 0.7
54.5 ± 0.8
18.4 ± 0.2
18.2 ± 0.3
18.6 ± 0.3
343 ± 3
342 ± 1
341 ± 1
24.2 ± 0.3*
24.8 ± 0.6
26.2 ± 0.5
15.9 ± 0.2
16.7 ± 0.3
16.4 ± 0.2
745 ± 111
791 ± 43
858 ± 83
8.54 ± 0.20
8.30 ± 0.11
8.38 ± 0.10
0.73 ± 0.04
0.66 ± 0.04
0.72 ± 0.07
PDW
(%)
P-LCR (%)
G1
G2
G3
G1
G2
G3
8.88 ± 0.15
8.73 ± 0.19
9.22 ± 0.24
11.0 ± 0.7
10.8 ± 0.8
12.0 ± 1.0
10.25 ± 0.17*
9.55 ± 0.20
9.48 ± 0.20
14.3 ± 1.0
12.9 ± 0.5
11.7 ± 0.5
9.13 ± 0.17
8.97 ± 0.14
8.87 ± 0.22
9.7 ± 0.9
9.2 ± 0.4
9.4 ± 0.9
10.18 ± 0.32
9.65 ± 0.23
9.67 ± 0.20
13.6 ± 1.7
11.7 ± 0.8
12.3 ± 0.9
Notes: Values are expressed as mean ± SE of 6 rats in each group. * and ** indicates a significant
difference at p < 0.05 and p < 0.01 level, respectively, when compared to G3 (vehicle control
group). WBC = white blood cells; NEU = neutrophils; LYM = lymphocytes; MON = monocytes;
EOS = eosinophils; BAS = basophils; RBC = red blood cells; HGB = ; HCT = hematocrit; MCV =
mean corpuscular volume; MCH = mean corpuscular hemoglobin; MCHC = mean corpuscular
hemoglobin content; RDW-SD = red blood cell distribution width standard deviation; RDW-CV =
coefficient of variation in erythrocyte distribution width; PLT = platelets; PDW = platelet distribution
width; P-LCR = large platelet ratio.
Table S4. Hematological parameters of female animals treated with bis-choline
tetrathiomolybdate
Test
Parameters
WBC (109/L)
NEU (%)
LYM
(%)
MON
(%)
EOS
(%)
BAS
(%)
NEU (109/L)
LYM (109/L)
MON (109/L)
EOS (109/L)
Female
Groups
G1
G2
G3
G1
G2
G3
G1
G2
G3
G1
G2
G3
G1
G2
G3
G1
G2
G3
G1
G2
G3
G1
G2
G3
G1
G2
G3
G1
G2
G3
Treatment
4 weeks
14.1 ± 1.0
10.0 ± 0.7
8.7 ± 0.6
7.2 ± 0.3
9.6 ± 0.8
8.5 ± 0.4
9.3 ± 0.5
7.3 ± 1.0
13.7 ± 1.2
11.2 ± 2.0
13.8 ± 2.2
14.9 ± 3.3
88.2 ± 0.7
89.7 ± 1.1
83.2 ± 1.2
84.9 ± 2.2
82.7 ± 2.4
81.2 ± 3.6
1.78 ± 0.25
1.80 ± 0.28
1.70 ± 0.28
2.30 ± 0.38
2.32 ± 0.27
2.40 ± 0.46
0.67 ± 0.10
1.08 ± 0.30
1.33 ± 0.18
1.55 ± 0.25
1.20 ± 0.25
1.43 ± 0.27
0.12 ± 0.02*
0.05 ± 0.02
0.05 ± 0.02
0.13 ± 0.02*
0.03 ± 0.02
0.05 ± 0.02
1.30 ± 0.08
0.72 ± 0.07
1.22 ± 0.15
0.78 ± 0.11
1.32 ± 0.24
1.25 ± 0.28
12.45 ± 0.95** 8.98 ± 0.70
7.23 ± 0.49
6.13 ± 0.34
8.00 ± 0.74
6.87 ± 0.46
0.27 ± 0.03
0.17 ± 0.03
0.15 ± 0.02
0.15 ± 0.02
0.22 ± 0.03
0.22 ± 0.05
0.10 ± 0.01
0.10 ± 0.02
0.12 ± 0.02
0.11 ± 0.02
0.11 ± 0.02
0.12 ± 0.02
Pre-dose
8 weeks
7.0 ± 0.5
4.8 ± 0.5
6.5 ± 0.6
11.3 ± 1.9
20.1 ± 3.5
15.3 ± 2.5
85.4 ± 2.6
75.5 ± 3.1
80.5 ± 2.9
1.83 ± 0.62
2.22 ± 0.21
2.40 ± 0.35
1.48 ± 0.29
1.98 ± 0.37
1.78 ± 0.32
0.02 ± 0.02
0.17 ± 0.10
0.00 ± 0.00
0.82 ± 0.18
0.90 ± 0.13
0.95 ± 0.11
5.93 ± 0.41
3.63 ± 0.49
5.30 ± 0.59
0.13 ± 0.05
0.12 ± 0.02
0.15 ± 0.02
0.10 ± 0.02
0.10 ± 0.02
0.11 ± 0.01
12 weeks
7.9 ± 1.0
5.3 ± 0.3
5.1 ± 0.8
11.8 ± 2.9
15.0 ± 2.5
12.9 ± 1.8
84.8 ± 3.1
79.7 ± 2.1
83.7 ± 2.0
2.07 ± 0.34
2.62 ± 0.25
1.82 ± 0.34
1.27 ± 0.19
2.65 ± 1.24
1.60 ± 0.15
0.03 ± 0.02
0.03 ± 0.03
0.02 ± 0.02
0.87 ± 0.17
0.78 ± 0.14
0.60 ± 0.07
6.82 ± 1.03
4.15 ± 0.24
4.30 ± 0.79
0.17 ± 0.03
0.13 ± 0.02
0.08 ± 0.03
0.10 ± 0.02
0.14 ± 0.07
0.08 ± 0.01
G1
BAS (109/L)
G2
G3
G1
RBC (1012/L) G2
G3
G1
HGB (g/L)
G2
G3
G1
HCT
G2
(%)
G3
G1
MCV
G2
(fL)
G3
G1
MCH
G2
(pg)
G3
G1
MCHC (g/L)
G2
G3
G1
RDW-SD (fL) G2
G3
G1
RDW-CV (%) G2
G3
G1
PLT (109/L)
G2
G3
G1
MPV
G2
(fL)
G3
G1
PCT
G2
(%)
G3
G1
PDW
G2
(%)
G3
G1
P-LCR (%)
G2
G3
0.02 ± 0.00*
0.01 ± 0.00
0.00 ± 0.00
7.60 ± 0.22
7.35 ± 0.18
7.77 ± 0.28
156 ± 2
147 ± 5
153 ± 4
45.0 ± 1.4
42.9 ± 1.1
44.6 ± 1.2
59.2 ± 0.5
58.4 ± 0.4
57.6 ± 0.6
20.6 ± 0.4
20.0 ± 0.2
19.8 ± 0.2
348 ± 7
342 ± 4
343 ± 2
25.4 ± 0.2
25.0 ± 0.4
24.5 ± 0.4
12.6 ± 0.2
12.6 ± 0.2
12.9 ± 0.4
621 ± 141
823 ± 44
845 ± 85
8.02 ± 0.10
7.92 ± 0.10
7.93 ± 0.11
0.50 ± 0.11
0.65 ± 0.04
0.67 ± 0.07
8.74 ± 0.25
8.48 ± 0.12
8.67 ± 0.19
10.2 ± 0.7
9.2 ± 0.6
9.3 ± 0.9
0.01 ± 0.00
0.01 ± 0.00
0.01 ± 0.00
7.70 ± 0.25
7.80 ± 0.17
8.07 ± 0.13
153 ± 5
154 ± 3
158 ± 2
45.0 ± 1.1
44.9 ± 0.9
45.6 ± 0.5
58.5 ± 0.8
57.5 ± 0.2
56.5 ± 0.6
19.9 ± 0.2
19.7 ± 0.1
19.5 ± 0.2
341 ± 3
343 ± 1
346 ± 3
25.4 ± 0.4
25.1 ± 0.3
24.1 ± 0.4
13.1 ± 0.2
13.1 ± 0.3
13.3 ± 0.3
873 ± 22
835 ± 42
790 ± 82
8.37 ± 0.12
8.42 ± 0.10
8.17 ± 0.11
0.73 ± 0.01
0.70 ± 0.03
0.65 ± 0.07
9.45 ± 0.27
9.52 ± 0.14
9.05 ± 0.19
11.8 ± 0.9
12.4 ± 0.8
10.4 ± 0.7
0.00 ± 0.00
0.01 ± 0.01
0.00 ± 0.00
7.09 ± 0.08**
7.62 ± 0.39
8.21 ± 0.20
138 ± 1**
147 ± 7
156 ± 4
40.9 ± 0.4**
42.5 ± 2.1
45.2 ± 0.9
57.8 ± 0.7*
55.7 ± 0.3
55.0 ± 0.5
19.5 ± 0.1
19.3 ± 0.1
19.0 ± 0.1
338 ± 2**
346 ± 2
346 ± 2
25.2 ± 0.5*
24.1 ± 0.3
23.3 ± 0.4
12.7 ± 0.2
13.3 ± 0.2
13.3 ± 0.3
774 ± 25
669 ± 92
747 ± 57
8.02 ± 0.10
7.97 ± 0.08
7.92 ± 0.07
0.62 ± 0.02
0.54 ± 0.07
0.59 ± 0.04
8.68 ± 0.19
8.68 ± 0.14
8.82 ± 0.19
9.5 ± 0.9
9.2 ± 0.7
8.9 ± 0.6
0.00 ± 0.00
0.00 ± 0.00
0.00 ± 0.00
7.73 ± 0.18
7.82 ± 0.18
7.97 ± 0.14
153 ± 3
151 ± 4
151 ± 3
44.9 ± 0.6
44.1 ± 1.0
44.4 ± 0.6
58.1 ± 0.6*
56.5 ± 0.4
55.7 ± 0.5
19.8 ± 0.1**
19.3 ± 0.1
18.9 ± 0.1
341 ± 2
341 ± 2
340 ± 3
25.6 ± 0.5
25.8 ± 0.2
24.9 ± 0.4
13.2 ± 0.4
14.1 ± 0.5
13.9 ± 0.2
754 ± 57
673 ± 116
783 ± 31
8.42 ± 0.10
8.53 ± 0.19
8.27 ± 0.11
0.63 ± 0.04
0.57 ± 0.09
0.65 ± 0.03
9.58 ± 0.21
10.03 ± 0.54
9.25 ± 0.19
12.3 ± 0.9
13.5 ± 1.5
11.0 ± 0.8
Notes: Values are expressed as mean ± SE of 6 rats in each group. * and ** indicates a significant
difference at p < 0.05 and p < 0.01 level, respectively, when compared to G3 (vehicle control
group). WBC = white blood cells; NEU = neutrophils; LYM = lymphocytes; MON = monocytes;
EOS = eosinophils; BAS = basophils; RBC = red blood cells; HGB = ; HCT = hematocrit; MCV =
mean corpuscular volume; MCH = mean corpuscular hemoglobin; MCHC = mean corpuscular
hemoglobin content; RDW-SD = red blood cell distribution width standard deviation; RDW-CV =
coefficient of variation in erythrocyte distribution width; PLT = platelets; PDW = platelet distribution
width; P-LCR = large platelet ratio.